At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 640 enrolled
Drug / intervention
Peanut Consumption Groupbiological
Likely dose
Peanut Consumption Group 2 gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Induction of Tolerance Through Early Introduction of Peanut in High-Risk Children (ITN032AD)
National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted May 25, 2006·Updated Apr 17, 2019
In Brief
A Phase 2 clinical trial evaluating Peanut Consumption Group for Eczema and 2 related conditions. Completed, enrolled 640 participants across 1 site.
Detailed Summary
This study will evaluate whether early exposure to peanuts promotes tolerance and provides protection from developing peanut allergy in children who are allergic to eggs or who have severe eczema. This study has been continued into the ITN049AD (LEAP-On) Study (NCT01366846).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEczema, Egg Allergy, Food Allergy
CountriesUnited Kingdom
CollaboratorsImmune Tolerance Network (ITN)
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 2006
Enrollment StartDec 2006
Primary CompletionMay 2014
TodayJul 2026
First PostedMay 25, 2006
Enrollment StartDec 1, 2006
Primary CompletionMay 1, 2014
TodayJul 2, 2026
Enrollment to primary: 7.4 yearsPosted 20.1 years ago
Interventions
Peanut Consumption Groupbiological
Peanut-containing snack. Children are to consume 2 g of peanut protein in three servings per week (total of 6 g) over 3 servings.